文献速递眼底病与葡萄膜炎

navigating Coronavirus Disease 2019 疫苗接种与葡萄膜炎:识别疫苗接种后复发性葡萄膜炎的发生率与风险

Navigating Coronavirus Disease 2019 Vaccination and Uveitis: Identifying the Rates and Risk of Recurrent Uveitis after Coronavirus Disease Vaccination.
PubMed 文献 · Ophthalmology · 2022-12-17

该回顾性研究纳入2010年1月1日至2020年12月31日在奥克兰地区卫生局炎症性眼病登记处诊断为葡萄膜炎的3008例患者共4184只眼,评估新冠疫苗接种前后3个月葡萄膜炎发作率。结果显示接种第一剂后发作率升高(基线12.3/1000患者月 vs 第一剂后20.7),风险因素包括复发性葡萄膜炎、慢性葡萄膜炎、较短静止期和第一剂疫苗。

要点

  • 接种第一剂新冠疫苗后葡萄膜炎发作率较基线升高(12.3 vs 20.7/1000患者月)。
  • 感染性与非感染性葡萄膜炎接种第一剂后发作率均升高(分别为13.1 vs 20.2和12.4 vs 20.9)。
  • 复发性葡萄膜炎、慢性葡萄膜炎、较短静止期和第一剂疫苗为发作风险因素。

核心结论

  • 本研究显示接种第一剂新冠疫苗后葡萄膜炎发作风险增加,风险在既往有复发、慢性葡萄膜炎和较短静止期者中最高。

研究设计与样本

  • 回顾性研究,纳入奥克兰地区卫生局炎症性眼病登记处2010年1月1日至2020年12月31日诊断为葡萄膜炎的3008例患者共4184只眼,研究期间共接种8474剂疫苗。

主要发现

  • 葡萄膜炎发作率基线为12.3/1000患者月,第一剂后20.7,第二剂后15.0,第三剂后12.8,第四剂后23.9。
  • 感染性葡萄膜炎发作率基线13.1 vs 第一剂后20.2(增加154%),非感染性葡萄膜炎基线12.4 vs 第一剂后20.9(增加169%)。
  • 发作前中位静止期为3.9年;第一剂后中位发作时间为0.53个月,第二剂后1.74个月,第三剂后1.35个月。
  • 发作风险因素包括复发性葡萄膜炎、慢性葡萄膜炎、较短静止期和第一剂疫苗。

关键数值与推荐

  • 葡萄膜炎发作定义为出现新的葡萄膜炎活动或活动增加且需要改变葡萄膜炎治疗。
  • 中位年龄54.8岁,女性1474例(49.0%);非感染性病因2296例(76.3%),感染性病因712例(23.7%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To identify rates of uveitis reactivation both before and after the coronavirus disease (COVID) 2019 vaccine in subjects with a previous diagnosis of uveitis. DESIGN: Retrospective study. PARTICIPANTS: Subjects were identified from the Inflammatory Eye Disease Registry at Auckland District Health Board diagnosed with uveitis between January 1, 2010, and December 31, 2020. METHODS: Date of COVID vaccination was determined from the patient clinical record. Rate of flare was calculated for 3 months before vaccination and 3 months after each vaccination. MAIN OUTCOME MEASURE: Uveitis flare was defined as the presence of new uveitis activity or increased activity that required a change in uveitis treatment. RESULTS: A total of 4184 eyes of 3008 patients were included in the study with a total of 8474 vaccinations given during the study period. Median age was 54.8 years, and 1474 (49.0%) were female. Noninfectious etiology was most common, occurring in 2296 patients (76.3%) and infectious etiology occurring in 712 patients (23.7%). Rate of uveitis flare was 12.3 per 1000 patient-months at baseline, 20.7 after the first dose, 15.0 after the second dose, 12.8 after the third dose, and 23.9 after the fourth dose. The median period of quiescence before flare was 3.9 years. An increase in uveitis flare was seen in both infectious uveitis (baseline 13.1 compared with 20.2 after first dose, 154% increase) and noninfectious uveitis (baseline 12.4 compared with 20.9 after first dose, 169% increase). Risk factors for uveitis flare were identified to be recurrent uveitis, chronic uveitis, shorter period of quiescence, and first dose of vaccine. Median time to uveitis flare was 0.53 months after the first vaccination, 1.74 months after the second vaccination, and 1.35 months after the third vaccination. CONCLUSIONS: The current study demonstrates an increased risk of uveitis flare after the first dose of COVID vaccination. This risk was highest in those with previous recurrences, chronic uveitis, and shorter period of quiescence. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Jordan CA, Townend S, Allen N, et al. Navigating Coronavirus Disease 2019 Vaccination and Uveitis: Identifying the Rates and Risk of Recurrent Uveitis after Coronavirus Disease Vaccination. Ophthalmology. 2022. PMID: 36538991. doi:10.1016/j.ophtha.2022.12.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。